Indian drug company completes CB buyback

Jubilant Organosys repurchases $48.3 million worth of convertible bonds and becomes the first Indian company to buy back CBs through a tender offer.

Indian pharmaceutical company Jubilant Organosys yesterday announced that it has repurchased $48.3 million worth of convertible bonds through a tender, bringing its outstanding debt down by approximately 20%. Following this transaction, its total remaining bonds outstanding are $193.2 million.
The buyback involved two bonds a $75 million CB due in 2010 and a $200 million CB due in 2011. The combined face value, $275 million, had been reduced to about $240 million through conversions and small buybacks in the...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition


  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...